AU2004281154A1 - 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer - Google Patents

2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Download PDF

Info

Publication number
AU2004281154A1
AU2004281154A1 AU2004281154A AU2004281154A AU2004281154A1 AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1 AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1
Authority
AU
Australia
Prior art keywords
compound
substituted
heteroaryl
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004281154A
Other languages
English (en)
Inventor
Savithri Ramurthy
Paul A. Renhowe
Sharadha Subramanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2004281154A1 publication Critical patent/AU2004281154A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004281154A 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Abandoned AU2004281154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51185103P 2003-10-16 2003-10-16
US60/511,851 2003-10-16
PCT/US2004/034185 WO2005037285A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2004281154A1 true AU2004281154A1 (en) 2005-04-28

Family

ID=34465285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004281154A Abandoned AU2004281154A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer

Country Status (10)

Country Link
US (3) US20050084835A1 (enExample)
EP (1) EP1680122A1 (enExample)
JP (1) JP2007509059A (enExample)
KR (1) KR20070029110A (enExample)
CN (1) CN1882345A (enExample)
AU (1) AU2004281154A1 (enExample)
CA (1) CA2542329A1 (enExample)
IL (1) IL174470A0 (enExample)
MX (1) MXPA06003607A (enExample)
WO (1) WO2005037285A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20060292537A1 (en) * 2005-06-27 2006-12-28 Arcturus Media, Inc. System and method for conducting multimedia karaoke sessions
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
TW200829566A (en) * 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
WO2008102353A2 (en) * 2007-02-20 2008-08-28 Mobile Star Corp. Self operated computerized karaoke recording booth
WO2009040290A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
AU2009226136B2 (en) 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
CA2748319A1 (en) 2008-12-29 2010-07-08 Fovea Pharmaceuticals Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation
EP2396324A1 (en) 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
WO2010144586A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
CN102625804B (zh) * 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
KR101630283B1 (ko) * 2009-06-25 2016-06-14 한화테크윈 주식회사 영상 보안 시스템에서 부호화 장치
DK2473504T3 (en) 2009-09-03 2015-03-16 Bioenergenix Heterocyclic Compounds for Inhibition of Passover
US8553906B2 (en) * 2010-02-02 2013-10-08 Creative Technology Ltd Apparatus for enabling karaoke
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
WO2012094462A2 (en) * 2011-01-05 2012-07-12 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012308238B2 (en) * 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013049701A1 (en) * 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CN103896922B (zh) * 2012-12-25 2017-05-03 上海科胜药物研发有限公司 新的舒尼替尼盐及其制备方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US20210353627A1 (en) * 2018-09-21 2021-11-18 Spectrum Pharmaceuticals, Inc. Novel quinazoline egfr inhibitors
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
WO2020214537A1 (en) * 2019-04-15 2020-10-22 Tosk, Inc. Modulators of ras gtpase
CN111072500B (zh) * 2019-11-15 2022-12-06 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
US12180220B2 (en) * 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2739505A (en) * 1952-02-04 1956-03-27 Gillette Edwin Method and means for producing composite talking pictures
GB900779A (en) * 1959-04-22 1962-07-11 Monsanto Chemicals Quinazolines
US3177218A (en) * 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
US4149190A (en) * 1977-10-17 1979-04-10 Xerox Corporation Automatic gain control for video amplifier
US4408221A (en) * 1981-09-22 1983-10-04 Mccoy Reginald F H Television chroma-key systems
DK190983A (da) * 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
US5051817A (en) * 1988-11-18 1991-09-24 Rohm Co., Ltd. Superimposing system
JP3206619B2 (ja) * 1993-04-23 2001-09-10 ヤマハ株式会社 カラオケ装置
JP3542821B2 (ja) * 1994-03-31 2004-07-14 ヤマハ株式会社 映像合成システムに特徴を有するカラオケ装置
US5541666A (en) * 1994-07-06 1996-07-30 General Instrument Method and apparatus for overlaying digitally generated graphics over an analog video signal
JP3662969B2 (ja) * 1995-03-06 2005-06-22 富士通株式会社 カラオケシステム
EP0767590A4 (en) * 1995-04-21 2000-11-29 Sony Corp METHOD AND CIRCUIT FOR PHASE SYNCHRONIZATION OF VIDEO SIGNALS AND COMBINATION DEVICE
US6400374B2 (en) * 1996-09-18 2002-06-04 Eyematic Interfaces, Inc. Video superposition system and method
JP2957977B2 (ja) * 1997-10-30 1999-10-06 三洋電機株式会社 ビデオカメラ
US6514083B1 (en) * 1998-01-07 2003-02-04 Electric Planet, Inc. Method and apparatus for providing interactive karaoke entertainment
NZ507760A (en) * 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020072047A1 (en) * 1999-12-13 2002-06-13 Michelson Daniel R. System and method for generating composite video images for karaoke applications
ES2246927T3 (es) * 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
US6978051B2 (en) * 2000-03-06 2005-12-20 Sony Corporation System and method for capturing adjacent images by utilizing a panorama mode
KR20020026374A (ko) * 2000-06-20 2002-04-09 요트.게.아. 롤페즈 가라오케 시스템
WO2002036570A1 (en) 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
ES2283543T3 (es) 2001-04-20 2007-11-01 Bayer Pharmaceuticals Corporation Inhibicion de raf kinasa usando quinolil-, isoquinolil- o piridil ureas.
US7035915B1 (en) * 2001-09-05 2006-04-25 Cisco Technology, Inc. Method and apparatus for IP address assignment
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
RU2356896C2 (ru) * 2003-04-16 2009-05-27 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
US20070047834A1 (en) * 2005-08-31 2007-03-01 International Business Machines Corporation Method and apparatus for visual background subtraction with one or more preprocessing modules
US7570881B2 (en) * 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use

Also Published As

Publication number Publication date
JP2007509059A (ja) 2007-04-12
WO2005037285A1 (en) 2005-04-28
EP1680122A1 (en) 2006-07-19
US20090317359A1 (en) 2009-12-24
IL174470A0 (en) 2006-08-01
US20050085482A1 (en) 2005-04-21
MXPA06003607A (es) 2006-06-05
US7691866B2 (en) 2010-04-06
US20050084835A1 (en) 2005-04-21
KR20070029110A (ko) 2007-03-13
CA2542329A1 (en) 2005-04-28
CN1882345A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
US7691866B2 (en) 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US7423150B2 (en) Substituted benzazoles and methods of their use as inhibitors of Raf kinase
CN100515419C (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
US8299108B2 (en) Substituted benzazoles and methods of their use as inhibitors of raf kinase
HK1067945B (en) Substituted benzazoles and use thereof as raf kinase inhibitors
HK1078779B (en) Substituted benzazoles and use thereof as raf kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application